Mercaptopurine (6-MP)

別名: 6-MP 中文名稱：巰嘌呤

目錄號：S1305 Purity: 99.97%

Mercaptopurine (6-MP)是一種廣泛應用于治療白血病的藥物，也是一種免疫抑制藥，通過整合巰基嘌呤的甲基轉(zhuǎn)移酶代謝產(chǎn)物進入DNA和RNA抑制新創(chuàng)嘌呤合成。

Mercaptopurine (6-MP) Chemical Structure

CAS: 50-44-2

規(guī)格	價格	庫存
10mM (1mL in DMSO)	818.52	現(xiàn)貨
50mg	784.59	現(xiàn)貨
1g	5487.3	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 info@selleck.cn

產(chǎn)品質(zhì)控

批次：純度： 99.97%

99.97

Mercaptopurine (6-MP)相關(guān)產(chǎn)品

相關(guān)靶點	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	點擊展開
相關(guān)產(chǎn)品	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) EED226 RK-33 BMH-21 Triapine (3-AP) Carmofur Thymidine YK-4-279 Mizoribine Halofuginone Tegafur (FT-207) Bergapten UNC1215 Azaguanine-8 Adenine HCl JH-RE-06 6-Thio-dG GSK6853 SU056 PCNA Antibody [N10L6] Nedaplatin APX-3330 Cyclocytidine HCl OF-1 GSK2801 Pritelivir (BAY 57-1293) Flupirtine maleate UNC669 Clevudine PFI-4 ML216 Phen-DC3 Trifluoromethanesulfonate CRT0044876 Tubercidin Nimustine Hydrochloride GSK 5959 D-I03 TK216 PFM01 CHD1Li 6.11 AGX51 Didox Adenine Amenamevir Madrasin GC7 Sulfate SCR130 BC-LI-0186	點擊展開
相關(guān)化合物庫	FDA藥物庫天然產(chǎn)物庫凋亡分子化合物庫 DNA損傷/ DNA修復化合物庫細胞周期化合物庫	點擊展開

細胞實驗數(shù)據(jù)示例

細胞系	實驗類型	孵育時間	活性描述
mouse J774.A1 cells	Proliferation assay	3 days	Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay, IC50=0.003 μM
HEK293 cells	Proliferation assay	3 days	Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay, IC50=0.007 μM
mouse J774 cells	Proliferation assay	72 h	Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method, IC50=0.003 μM
human PBMC	Function assay	4 days	Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days, IC50=0.1495 μM
HeLa cells	Cytotoxicity assay	48 h	Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay, IC50=2.9 μM
A549 cells	Cytotoxicity assay	48 h	Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay, IC50=47 μM
MCF7 cells	Cytotoxicity assay	48 h	Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay, IC50=1.4 μM
MT4 cells	Cytotoxicity assay	96 h	Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay, CC50=0.1 μM
CCRF-CEM cells	Proliferation assay	96 h	Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay, CC50=1 μM
WIL2-NS cells	Proliferation assay	96 h	Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay, CC50=3 μM
CCRF-SB cells	Proliferation assay	96 h	Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay, CC50=1.1 μM
human DU145 cells	Proliferation assay	96 h	Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay, CC50=2 μM
human HepG2 cells	Proliferation assay	96 h	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay, CC50=8 μM
MCF7 cells	Proliferation assay	96 h	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay, CC50=3.2 μM
SK-MEL-28 cells	Proliferation assay	96 h	Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay, CC50=15 μM
mouse S49 cells	Cytotoxicity assay	72 h	Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay, EC50=8 μM
A549 cells	Cytotoxicity assay	48 h	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay, IC50=47 μM
MCF7 cells	Cytotoxicity assay	48 h	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay, IC50=1.4 μM
HeLa cells	Cytotoxicity assay	48 h	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay, IC50=2.9 μM
WEHI164 cells	Proliferation assay	3 days	Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay, IC50=0.015 μM
WEHI164 cells	Proliferation assay	72 h	Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method, IC50=0.017 μM
L1210 leukemia cells	Function assay		Inhibitory concentration on multidrug-resistant L1210 leukemia cells, IC50=0.024 μM
MT4 cells	Proliferation assay		Antiproliferative activity against human MT4 cells by MTT assay, IC50=0.1 μM
human CCRF-CEM cells	Proliferation assay		Antiproliferative activity against human CCRF-CEM cells by MTT assay, IC50=1 μM
human CCRF-SB cells	Proliferation assay		Antiproliferative activity against human CCRF-SB cells by MTT assay, IC50=1 μM
human SK-MEL-28 cells	Proliferation assay		Antiproliferative activity against human SK-MEL-28 cells by MTT assay, IC50=15 μM
human MCF7 cells	Proliferation assay		Antiproliferative activity against human MCF7 cells by MTT assay, IC50=3 μM
human HepG2 cells	Proliferation assay		Antiproliferative activity against human HepG2 cells by MTT assay, IC50=8 μM
human DU145 cells	Proliferation assay		Antiproliferative activity against human DU145 cells by MTT assay, IC50=2 μM
MCF7 cells	Cytotoxicity assay		Cytotoxicity against human MCF7 cells, IC50=2.79 μM
Colo-357 cells	Cytotoxicity assay		Cytotoxicity against human Colo-357 cells by crystal violet staining, IC50=6.12 μM
Aspc-1 cells	Cytotoxicity assay		Cytotoxicity against human Aspc-1 cells by crystal violet staining, IC50=2.45 μM
Patu-02 cells	Cytotoxicity assay		Cytotoxicity against human Patu-02 cells by crystal violet staining, IC50=9.69 μM
Patu-T cells	Cytotoxicity assay		Cytotoxicity against human Patu-T cells by crystal violet staining, IC50=4.09 μM
Patu-S cells	Cytotoxicity assay		Cytotoxicity against human Patu-S cells by crystal violet staining, IC50=11.07 μM
T3M4 cells	Cytotoxicity assay		Cytotoxicity against human T3M4 cells by crystal violet staining, IC50=2.63 μM
human PANC1 cells	Cytotoxicity assay		Cytotoxicity against human PANC1 cells by crystal violet staining, IC50=6.39 μM
human DAN-G cells	Cytotoxicity assay		Cytotoxicity against human DAN-G cells by crystal violet staining, IC50=4.06 μM
WIL-2NS cells	Proliferation assay		Antiproliferative activity against human WIL-2NS cells by MTT assay, IC50=3 μM
點擊查看更多細胞系數(shù)據(jù)

生物活性

產(chǎn)品描述

靶點

PRPP Amidotransferase

體外研究(In Vitro)
體外研究活性	Mercaptopurine被廣泛用于治療惡性腫瘤，風濕性疾病，皮膚病，炎癥性腸道疾病，以及實體器官移植排斥。 Mercaptopurine通過抑制磷酸核糖焦磷酸酰胺轉(zhuǎn)移酶（PRPP酰胺轉(zhuǎn)移酶）而抑制嘌呤核苷和代謝。PRPP酰胺轉(zhuǎn)移酶是嘌呤合成的限速酶。它會改變RNA和DNA的合成和功能。Mercaptopurine干擾核苷酸的互變和糖蛋白的合成。

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試驗信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04770922	Completed	Acute Lymphoblastic Leukemia Pediatric\|Adverse Drug Event	Cipherome Inc.\|Stanford University	February 23 2021	--
NCT03022747	Unknown status	Lymphoblastic Leukemia Acute Childhood	Vastra Gotaland Region	January 2017	Phase 2

參考文獻
[1]https://pubmed.ncbi.nlm.nih.gov/18506437/ [2]https://pubmed.ncbi.nlm.nih.gov/7191632/

參考文獻

[1]https://pubmed.ncbi.nlm.nih.gov/18506437/
[2]https://pubmed.ncbi.nlm.nih.gov/7191632/

化學信息&溶解度

分子量	152.18	分子式	C₅H₄N₄S
CAS號	50-44-2	SDF	Download Mercaptopurine (6-MP) SDF
Smiles	C1=NC2=C(N1)C(=S)N=CN2
儲存條件(自收到貨起)	3年-20°C粉狀	儲備液保存和期限建議分裝儲備液，避免反復凍融！	1年-80°C溶于溶劑
儲存條件(自收到貨起)	3年-20°C粉狀	儲備液保存和期限建議分裝儲備液，避免反復凍融！	1個月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 30 mg/mL ( (197.13 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 25 mg/mL ( (164.27 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計算器

體內(nèi)溶解配方批次：現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑				動物體內(nèi)配方計算器
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
澄清溶液	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O 該配方已經(jīng)過Selleck實驗室實測。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測試。	1.250mg/ml (8.21mM)	以 1 mL 工作液為例,取50μL25mg/ml的澄清DMSO儲備液加到400μLPEG300中,混合均勻使其澄清;向上述體系中加入50μLTween80,混合均勻使其澄清;然后繼續(xù)加入500μLddH2O定容至1mL。工作液請現(xiàn)配現(xiàn)用!
澄清溶液	5% DMSO 1 95% Corn oil 該配方已經(jīng)過Selleck實驗室實測。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測試。	0.208mg/ml (1.37mM)	以1 mL工作液為例，取50μL 4.16mg/ml的澄清DMSO儲備液加到950μL玉米油中，混合均勻。工作液請現(xiàn)配現(xiàn)用！

實驗計算

摩爾濃度計算器

質(zhì)量	濃度	體積	分子量
=	×	×

稀釋計算器分子量計算器

動物體內(nèi)配方計算器（澄清溶液）

第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）

給藥劑量 mg/kg 動物平均體重 g 每只動物給藥體積 μL 動物數(shù)量只

第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。

操作手冊

如果有其他問題，請給我們留言。

* 必填項

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线